North America Diltiazem Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Capsules, Injection, and Tablets) and Application (Angina, Hypertension, and Others)
Market Introduction
Diltiazem is a benzothiazepine derivative that acts as an antihypertensive and vasodilator. Diltiazem is an antihypertensive and vasodilator that lowers blood pressure by relaxing the vascular muscle. This is due to the long-term therapeutic effects of decreasing blood pressure since it lowers the risk of fatal and non-fatal cardiovascular events, such as strokes and myocardial infarction. According to in vitro binding experiments, diltiazem is 70%-80% bound to plasma proteins. At clinically relevant concentrations, around 40% of the medication is thought to attach to alpha-1-glycoprotein, whereas about 30% of the drug is thought to bind to albumin.
Get more information on this report :
Market Overview and Dynamics
The North America diltiazem market is expected to reach US$ 369.22 million by 2028 from US$ 161.53 million in 2021; it is estimated to grow at a CAGR of 12.5% from 2021 to 2028. Rise in government initiatives for promotion, increase in the prevalence of cardiovascular diseases, and rise in the elderly population with heart diseases worldwide are expected to boost the market growth over the years. However, the side effects of Diltiazem on consumption are likely to impact the market's growth in the coming years negatively.
Diltiazem has potential use in a wide variety of cardiovascular disorders. According to the World Health Organization, cardiovascular diseases (CVDs) are the number one cause of death worldwide. CVDs are a major cause of morbidity and affect more people than any other disease. Tobacco consumption, unhealthy diet, and physical inactivity are major lifestyle factors that increase the risk of heart attacks and strokes. In addition, other risk factors that can lead to cardiovascular diseases are high blood pressure, diabetes, and increased cholesterol levels. The Centers for Disease Control and Prevention (CDC) estimated that around 2.7–6.1 million people were suffering from Atrial fibrillation (AFib) in the US in 2019. Every year, over 454,000 hospitalizations and about 158,000 deaths are reported due to AFib in the US. The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan and Apoptin) effectively control the initial ventricular rate in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.
Furthermore, Diltiazem reduces conduction in the atrioventricular node, which is also useful for heart rate control in patients with atrial fibrillation. Thus, the increasing prevalence of atrial fibrillation across the globe drives the diltiazem market. Also, the elderly population is more prompt to have atypical presentations, comorbid conditions, and unfavorable outcomes. Structural and functional changes in the cardiovascular system associated with aging are major causes of cardiovascular diseases. Therefore, the rising geriatric population worldwide is leading to an increase in the incidence of cardiovascular disease, bolstering the growth of the diltiazem market.
In North America, the US was highly influenced by the eruption of the COVID-19 pandemic. The COVID-19 pandemic has created technological shifts crucial to providing better care. Given the current pandemic and the need for practicality, the drugs should ideally be FDA approved so they can be rapidly repurposed for COVID-19 treatment. SARS-CoV requires Ca2+ ions for host cell entrance and based on the connection between SARS-CoV and SARS-CoV-2, it is very likely that the exact necessities exist for both viruses. Moreover, as per the recent report of bioRxiv published in July 2020, there is evidence that calcium channel blockers (CCB) inhibit viral infections at the cell entry level. Therefore, treatment with verapamil or Diltiazem inhibits viral infection. Hypertension was among the general comorbidities seen in COVID-19 infected patients. Diltiazem may be helpful to treat hypertension associated with COVID-19. Since the COVID-19 outbreak reached the pandemic status, the entire global supply chain has been affected; however, various pharmaceutical companies are developing vaccines and drugs to combat the pandemic. Therefore, COVID-19 has had a substantial positive impact on the diltiazem market.
Key Market Segments
Based on product, the North America diltiazem market is segmented into capsules, injection, and tablets. In 2021, the tablets segment held the largest share of the market. However, the capsules segment is expected to witness the fastest CAGR from 2021 to 2028.
Based on application, the North America diltiazem market was segmented into angina, hypertension, and others. In 2021, the hypertension segment held the largest share of the market. The angina segment is expected to grow at the fastest CAGR during the coming years.
Major Sources and Companies Listed
A few of the primary and secondary sources associated with this report on the North America diltiazem market are the United States Food & Drug Administration (USFDA), Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services (HHS), and Canadian Institutes of Health Research (CIHR), among others.
Reasons to buy the report
- Determine prospective investment areas based on a detailed trend analysis of North America diltiazem market over the next years.
- Gain an in-depth understanding of the underlying factors driving demand for different addictions therapeutics segments in the top spending countries and identify the opportunities offered by each of them.
- Strengthen your knowledge of the market in terms of demand drivers, industry trends, and the latest technological developments, among others.
- Identify the major channels driving the North America diltiazem market, providing a clear picture of future opportunities that will help analyze, resulting in revenue expansion.
- Channelize resources by focusing on the ongoing programs undertaken by the different countries within the North America diltiazem market.
NORTH AMERICA DILTIAZEM MARKET SEGMENTATION
By Product Type
- Tablet
- Capsules
- Injection
By Application
- Hypertension
- Angina
- Others
By Country
- US
- Canada
- Mexico
Company Profiles
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
- Athenex
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Diltiazem Market – By Product Type
1.3.2 North America Diltiazem Market – By Application
1.3.3 North America Diltiazem Market – By Country
2. North America Diltiazem Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Diltiazem Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America – PEST Analysis
4.3 Experts Opinion
5. Diltiazem Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Cardiovascular Disease Incidence
5.1.2 Increasing Elderly Population
5.2 Market Restraints
5.2.1 Side Effects of Diltiazem
5.3 Future Trends
5.3.1 Recent Developments in Market
5.4 Impact Analysis
6. Diltiazem Market – North America Analysis
6.1 North America Diltiazem Market Revenue Forecast and Analysis
7. Diltiazem Market Analysis and Forecasts to 2028 – Product Type
7.1 Overview
7.2 Diltiazem Market Share by Product Type 2021 & 2028 (%)
7.3 Capsules
7.3.1 Overview
7.3.2 Capsules Market Revenue and Forecast to 2028 (US$ Mn)
7.4 Injection
7.4.1 Overview
7.4.2 Injection Market Revenue and Forecast to 2028 (US$ Mn)
7.5 Tablets
7.5.1 Overview
7.5.2 Tablet Market Revenue and Forecast to 2028 (US$ Mn)
8. Diltiazem Market Analysis and Forecasts to 2028 – Application
8.1 Overview
8.2 Diltiazem Market Share by Application 2021 & 2028 (%)
8.3 Angina
8.3.1 Overview
8.3.2 Angina Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Hypertension
8.4.1 Overview
8.4.2 Hypertension Market Revenue and Forecast to 2028 (US$ Mn)
8.5 Others
8.5.1 Overview
8.5.2 Others Market Revenue and Forecast to 2028 (US$ Mn)
9. Diltiazem Market – North America Analysis
9.1 North America: Diltiazem Market
9.1.1 Overview
9.1.2 North America: Diltiazem Market, by Country, 2021 & 2028 (%)
9.1.2.1 US: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.1 US: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.2 US Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.2.1.3 US Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.2.2 Canada: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.1 Canada: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.2 Canada Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.2.2.3 Canada Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
9.1.2.3 Mexico: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.1 Mexico: Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.2 Mexico Diltiazem Market, by Product Type– Revenue and Forecast to 2028 (USD Million)
9.1.2.3.3 Mexico Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
10. Impact Of COVID-19 Pandemic on North America Diltiazem Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Diltiazem Market–Industry Landscape
11.1 Overview
11.2 Recent Growth Strategies in The Diltiazem Market
12. Company Profiles
12.1 Bausch Health Companies Inc.
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Teva Pharmaceutical Industries Ltd
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 MYLAN N.V.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4
12.5 Pfizer Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Sandoz (Novartis AG)
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Sun Pharmaceutical Industries Ltd
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Hikma Pharmaceuticals PLC
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Zydus Cadila
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Glenmark
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
12.11 Athenex
12.11.1 Key Facts
12.11.2 Business Description
12.11.3 Products and Services
12.11.4 Financial Overview
12.11.5 SWOT Analysis
12.11.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. US Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 2. US Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 3. Canada Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 4. Canada Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 5. Mexico Diltiazem Market, by Product Type – Revenue and Forecast to 2028 (USD Million)
Table 6. Mexico Diltiazem Market, by Application– Revenue and Forecast to 2028 (USD Million)
Table 7. Glossary of Terms, Diltiazem Market
LIST OF FIGURES
Figure 1. Diltiazem Market Segmentation
Figure 2. Diltiazem Market Segmentation, By Country
Figure 3. North America Diltiazem Market Overview
Figure 4. Tablets Held the Largest Share of the Product Segment in Diltiazem Market
Figure 5. North America Diltiazem Market – Leading Country Markets (US$ Million)
Figure 6. North America PEST Analysis
Figure 7. Diltiazem Market: Impact Analysis of Drivers and Restraints
Figure 8. North America Diltiazem Market – Revenue Forecast and Analysis – 2020- 2028
Figure 9. Diltiazem Market Share by Product Type 2021 & 2028 (%)
Figure 10. Capsules Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 11. Injection Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 12. Tablet Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 13. Diltiazem Market Share by Application 2021 & 2028 (%)
Figure 14. Angina Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Hypertension Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 16. Others Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 17. North America: Diltiazem Market, by Key Country – Revenue (2021) (USD Million)
Figure 18. North America: Diltiazem Market, by Country, 2021 & 2028 (%)
Figure 19. US Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 20. Canada Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 21. Mexico Diltiazem Market – Revenue and Forecast to 2028 (USD Million)
Figure 22. Impact of COVID-19 Pandemic in North American Country Markets
- Bausch Health Companies Inc.
- Teva Pharmaceutical Industries Ltd
- MYLAN N.V.
- Pfizer Inc.
- Sandoz (Novartis AG)
- Sun Pharmaceutical Industries Ltd
- Hikma Pharmaceuticals PLC
- Zydus Cadila
- Glenmark
- Athenex
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America diltiazem market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the North America diltiazem market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.